Figure 3.

ML2B7-Fluc Leukemia Cells Are Susceptible to Treatment with VSV and CD8⁺ T cm

ML2B7-Fluc cells were infected with indicated MOIs of rVSV-tk. (A) Cell viability was assayed by measuring the luciferase activity of viable tumor cells. The means ± SD from three independent experiments, performed in triplicates, are shown. Two-way ANOVA with Bonferroni post-test was performed to determine statistical significance (**p < 0.01; ****p < 0.0001). (B) Virus titers in culture supernatants at the indicated time points were assayed by TCID₅₀. Means ± SD from three individual experiments, performed in triplicates, are shown. (C) Luciferase assays were performed to determine the number of viable ML2B7-Fluc tumor cells 24 hr after treatment with indicated treatment groups. TCR transduced and control T cells were uninfected or infected with rVSV-tk at an MOI of 0.1 before being added in a 1:20 ratio to the tumor cells. Individual replicates and means ± SD from three experiments performed in triplicates from three different T cell donors are shown. The percentage of living cells was normalized to untreated control cells. One-way ANOVA with Bonferroni post-test was performed (*p < 0.05; ***p < 0.001). (D) Viral titers from co-culture supernatants were measured by TCID₅₀. Individual replicates and means ± SD are shown. Statistical analysis was performed using unpaired t test (**p < 0.01). (E) IFN-γ concentrations in coculture supernatants were measured by ELISA assay. Means ± SD are shown.